Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Major Depressive Disorder Clinical Trials

22 recruiting trials for Major Depressive Disorder. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
22
Total Trials
22
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT06402955

Imaging Depression in Parkinson's Disease

The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the...

Sponsor: Yale UniversityEnrolling: 1201 location
RECRUITINGNCT05051618

Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis

The purpose of this research is to examine the effects of two different exercise training regimens for managing depression and improving other health indicators among persons with...

Sponsor: University of Illinois at ChicagoEnrolling: 1461 location
RECRUITINGNCT06159595

Behavioral and Neuronal Correlates of Human Mood States

Optimizing treatments in mental health requires an easy to obtain, continuous, and objective measure of internal mood. Unfortunately, current standard-of-care clinical scales are...

Sponsor: Stanford UniversityEnrolling: 101 location
RECRUITINGPhase 4NCT05892744

Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug...

Sponsor: University of Texas at AustinEnrolling: 501 location
RECRUITINGEarly Phase 1NCT03748446

Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder

The investigators will test the hypothesis that inhaled xenon will produce a rapid improvement in depressive symptoms in patients suffering from treatment-resistant depression....

Sponsor: Massachusetts General HospitalEnrolling: 201 location
RECRUITINGNCT07221929

Exercise-priming of CBT for Depression: the CBT+ Trial

This study investigates the effects of intentionally sequencing aerobic exercise immediately prior to cognitive behavioral therapy (CBT) to determine its effects on mechanisms of...

Sponsor: University of Wisconsin, MadisonEnrolling: 1001 location
RECRUITINGEarly Phase 1NCT05327699

Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive...

Sponsor: Emory UniversityEnrolling: 1401 location
RECRUITINGPhase 2NCT07276997

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major...

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause...

Sponsor: AbbVieEnrolling: 19520 locations
RECRUITINGPhase 2NCT07493317

Neutralizing Interleukin (IL)-6

The proposed study aims to establish the feasibility and safety of subcutaneous tocilizumab, a monoclonal antibody (mAb) against interleukin (IL)-6 receptor, in adults with Major...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 601 location
RECRUITINGEarly Phase 1NCT07017478

Mood Effects of Serotonin Agonists: Depression

This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The...

Sponsor: University of ChicagoEnrolling: 481 location
RECRUITINGNCT05680220

40 Hz Light Neurostimulation for Patients With Depression (FELIX)

Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression,...

Sponsor: Klaus MartinyEnrolling: 601 location
RECRUITINGNCT05773755

DBS for TRD With the Medtronic Percept PC

Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of...

Sponsor: Helen Mayberg, MDEnrolling: 101 location
RECRUITINGNCT06897670

Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared...

The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional...

Sponsor: Mayo ClinicEnrolling: 2001 location
RECRUITINGNCT05409794

Basal Plasma Lithium Levels and Suicidal Events

Suicidal behavior is a major public health issue and there are currently no specific treatments for it. However, lithium, the reference treatment for bipolar disorder, have been...

Sponsor: University Hospital, MontpellierEnrolling: 1581 location
RECRUITINGNCT07316803

Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness

This study evaluates a group-based intervention designed to improve romantic and social relationship skills in adults living with a severe mental illness (SMI), such as...

Sponsor: Centre hospitalier de Ville-Evrard, FranceEnrolling: 202 locations
RECRUITINGPhase 4NCT07105111

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain...

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

Sponsor: Neurocrine BiosciencesEnrolling: 5019 locations
RECRUITINGPhase 4NCT06417437

Non-invasive BCI and Application Verification for Depressed People

Major Depressive Disorder (MDD) is a serious mental illness and public health problem that poses threat to both physical and mental health. According to statistics from WHO, it is...

Sponsor: Shanghai Mental Health CenterEnrolling: 4001 location
RECRUITINGNCT03601026

Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use

Severe mental illness (SMI) refers to the most burdensome psychiatric conditions. The need to pre-empt the onset of SMI is pressing because once SMI develops, quality of life is...

Sponsor: Nova Scotia Health AuthorityEnrolling: 1201 location
RECRUITINGPhase 4NCT04828226

Clonidine to Prevent Delirium After Electroconvulsive Therapy.

Electroconvulsive therapy (ECT) is a highly effective treatment for some psychiatric disorders like major depressive or bipolar disorder, but may lead to agitation and delirium...

Sponsor: Insel Gruppe AG, University Hospital BernEnrolling: 1301 location
RECRUITINGNCT06763081

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation

The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in...

Sponsor: University of ManitobaEnrolling: 1602 locations
RECRUITINGNCT05437705

Decoding and Modulating Affective Brain States

The research study is being conducted to study brain patterns of negative emotion and develop personalized brain stimulation protocols to disrupt these patterns with transcranial...

Sponsor: University of PennsylvaniaEnrolling: 401 location
RECRUITINGNCT06045897

EEG Microstates Across At-Risk Mental States

The goal of this observational study is to compare subjects with at-risk-mental-state, early psychosis, schizophrenia, depression, and autism spectrum disorders, with healthy...

Sponsor: Centre Hospitalier St AnneEnrolling: 1261 location

Frequently Asked Questions

There are currently 22 clinical trials for Major Depressive Disorder, with 22 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Major Depressive Disorder, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Major Depressive Disorder, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

this entity is one of the data points covered by this site’s U.S. clinical trials and research registries dataset. The detail above comes directly from the NIH ClinicalTrials.gov registry; the context that follows situates the headline numbers against the broader distribution across active and historical clinical trials.

The methodology behind every numeric value on this page is publicly documented on the the NIH ClinicalTrials.gov registry portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.